Answers are grounded in this paper and cite their sources.
Recent trials have shown that low-dose colchicine (0.5 mg once daily) reduces major cardiovascular events in patients with acute and chronic coronary syndromes. We aimed to estimate the cost-effectiveness of low-dose colchicine therapy in patients with chronic coronary disease when added to standard background therapy.
No takes yet. Share an insight, caveat, or question.
Fiolet et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: